|
Orphan Drugs in Asia-Pacific: From Designation to Pricing, Funding & Market Access |
|
It is estimated that 6-10% of the world’s population will suffer from a rare disease at one point in life. On this basis, the markets of Asia-Pacific should offer great potential to companies developing orphan drugs. The region’s population is 4 billion, nearly two-thirds of the global total, so even the rarest disease will have many patients seeking treatment.
|
|
Read more...
|
|
|
Pharmaceutical Pricing & Distribution in Japan: The Keys to Success in the World’s Second Largest Market |
|
No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for developing and marketing medicines dominated by price.
|
|
Read more...
|
|
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues |
|
In order to raise public awareness, 29 February 2008 was dedicated the first European rare disease day (‘a rare day for very special people’), but European payers need no reminding of the significance of rare disease treatments, generally known as orphan drugs.
|
|
Read more...
|
|
Pharmacy Liberalisation in Europe: Prospects and Implications |
|
Very little in the pricing environment in Europe is predictable to pharmaceutical companies and only rarely is much notice given of change.
|
|
Read more...
|
|
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006 |
|
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006 examines the key issues that need to be addressed by pharmaceutical and biotechnology companies alike in order to successfully achieve return on investment.
|
|
Read more...
|
|
|
|
|
